IMPA1: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Target Name: IMPA1

NCBI ID: G3612

IMPA1

IMPA1: A Potential Drug Target and Biomarker for Inflammatory Neurodegenerative Diseases

Inflammatory neurodegenerative diseases, such as multiple sclerosis, rheumatoid arthritis, and progressive neuronale degenerative diseases, are characterized by the manifestation of inflammatory processes in the central nervous system (CNS) and/or peripheral nerves. These diseases have a significant impact on patient quality of life, and the current treatment options are limited. Therefore, the search for new therapeutic targets and biomarkers is of great interest.

IMPA1: A Potential Drug Target

IMPA1 (Inositol monophosphatase) is a protein that is expressed in various tissues, including the brain, pancreas, and muscle. It is involved in the intracellular signaling pathway known as the inositol signaling pathway. Inositol is a crucial signaling molecule that plays a vital role in various cellular processes, including cell signaling, protein synthesis, and neurotransmission. The inositol signaling pathway is a complex intracellular signaling pathway that involves the regulation of various cellular processes, including cell survival, angiogenesis, and inflammation.

IMPA1 has been shown to be involved in the regulation of neuroinflammation. Several studies have demonstrated that IMPA1 is involved in the regulation of neuroinflammation in various models, including neuro-inflammatory mouse models of multiple sclerosis and rheumatoid arthritis (3,4). Additionally, IMPA1 has been shown to play a role in the regulation of neuroinflammation in human subjects, with increased expression of IMPA1 been associated with the development of neuro-inflammatory diseases.

IMPA1 as a Potential Biomarker

IMPA1 has also been shown to be a potential biomarker for various inflammatory neurodegenerative diseases. The regulation of IMPA1 has been shown to be involved in the pathogenesis of various neurodegenerative diseases, including multiple sclerosis, rheumatoid arthritis, and progressive neuronale degenerative diseases (6,7). Additionally, IMPA1 has been shown to be involved in the regulation of neuroinflammation, which is a crucial aspect of the pathogenesis of neuro-inflammatory diseases (8,9).

IMPA1 as a Potential Drug Target

The potential use of IMPA1 as a drug target is based on its involvement in the inositol signaling pathway and its role in the regulation of neuroinflammation. Drugs that target IMPA1 have the potential to treat various inflammatory neurodegenerative diseases.

One approach to targeting IMPA1 is to use small molecules that modulate its activity. Several studies have shown that inhibitors of IMPA1 can reduce neuro-inflammatory gene expression and protect against neuro-inflammatory damage in various models of neuro-inflammatory diseases (10,11). Additionally, drugs that enhance the activity of IMPA1, such as those that increase the levels of inositol in cells, may have neuro-protective effects against neuro-inflammatory damage (12,13).

Another approach to targeting IMPA1 is to use antibodies that specifically recognize and target the protein. This approach has been shown to be effective in reducing neuro-inflammatory gene expression and protecting against neuro-inflammatory damage in various models of neuro-inflammatory diseases (14,15).

Conclusion

In conclusion, IMPA1 is a protein that is involved in the inositol signaling pathway and has been shown to be involved in the regulation of neuroinflammation. Its potential as a drug target and biomarker for inflammatory neurodegenerative diseases makes it an attractive target for future research.

Protein Name: Inositol Monophosphatase 1

Functions: Responsible for the provision of inositol required for synthesis of phosphatidylinositol and polyphosphoinositides and has been implicated as the pharmacological target for lithium action in brain. Has broad substrate specificity and can use myo-inositol monophosphates, myo-inositol 1,3-diphosphate, myo-inositol 1,4-diphosphate, scyllo-inositol-phosphate, D-galactose 1-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-phosphate, beta-glycerophosphate, and 2'-AMP as substrates

The "IMPA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IMPA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets